TOKYO U.S. crude futures fell in early trade on Thursday, giving up some of gains from the previous day as surging COVID-19 cases and widening lockdowns raised fears over fuel demand, offsetting further upbeat vaccine news.
TOKYO Oil prices fell on Wednesday after a bigger-than-expected build in U.S. crude stockpiles stoked fears for weak fuel demand and a potential supply glut, but hopes that OPEC and its allies will postpone a planned January increase to oil output braked losses.
* Aims to boost wind power capacity to 1 GW in FY30/31 (Adds background, detail)
TOKYO, Nov 11 Japan's Tohoku Electric Power said on Wednesday it had received the green light from a local governor to restart one of its nuclear reactors, nearly a decade after it was damaged in the earthquake and tsunami that caused the Fukushima disaster.
TOKYO Japan's oil and metals giant Eneos Holdings Inc on Wednesday more than doubled its net profit forecast for the year to next March, saying it expected an appraisal gain on its oil inventories because of higher-than-expected crude prices.
TOKYO, Nov 11 Japan's oil and metals giant Eneos Holdings Inc on Wednesday more than doubled its net profit forecast for the year to next March, saying it expected an appraisal gain on its oil inventories because of higher-than-expected crude prices.
* Raises FY crude steel output plan to T32.7 mln from T31.8 mln (Recasts with earnings and quotes)
TOKYO/SHANGHAI Oct 30 Rubber prices have rocketed to their highest in over three years as protective glove demand surges due to the COVID-19 crisis and industrial use rebounds in China, while supplies remain tight with producers struggling to replenish stocks.
TOKYO Prime Minister Yoshihide Suga is set to bind Japan to a target for carbon neutrality by 2050, a shift in stance that will bring the country in line with the European Union and more than 60 other nations in efforts to combat climate change.
* September output down 19% y/y to 6.49 mln T, but up from August
Britain gave AstraZeneca's COVID-19 vaccine a vote of confidence on Friday when it asked its regulator to assess the shot for a rollout after experts raised questions about trial data and the company said it may run another study to gauge efficacy.